“For example, the most well-known of these immunotherapies only benefits 20 to 30% of patients.” When they delivered the Cas13 package into tumor microenvironments in mice, they found that it silenced ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

We demonstrate that RNA-targeting CRISPR effector Cas13 can be engineered for RNA diagnostics and mammalian cell RNA knockdown, binding, and editing. We demonstrate diagnostic applications of Cas13 ...